Eris Lifesciences Ltd

Eris Lifesciences Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from July 01, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ending June 30, 2026. All concerned individuals are advised not to trade in the company's securities during this period. This notice is independent of any other trading window closure announcements.

Eris Lifesciences Ltd has released a corporate presentation detailing its business segments, including Domestic Branded Formulations and International Business. The company highlights its strong market position in Anti-Diabetes therapy and Insulins, with a 6% and 16% market share respectively. It also notes a strong start for its Gx Semaglutide brand, Sundae. The presentation outlines significant investments and leveraged acquisitions totaling over ₹4,300 crore between FY23-FY26, aimed at entering high-value therapies and expanding its business, including recent entries into the Derma segment and acquisitions of injectable and other businesses. The company also emphasizes its R&D capabilities and state-of-the-art manufacturing facilities.

Eris Lifesciences Limited has been fined ₹4,24,800 each by BSE and NSE for non-compliance with Regulation 17(1) of SEBI Listing Regulations concerning the composition of its Board of Directors for the quarter ended March 31, 2026. The company clarified that the non-compliance arose from a board vacancy due to an Independent Director's term completion, which has since been filled on March 14, 2026. Eris Lifesciences states it is now compliant and remains committed to regulatory adherence. The financial impact is limited to the penalty amount.

Eris Lifesciences Ltd's board approved and recorded the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. An interim dividend of ₹7.21 per share (721%) was declared for FY26-27, with a record date of May 29, 2026, and payment on or before June 19, 2026. The audit reports have unmodified opinions. The board meeting occurred on May 20, 2026, from 11:00 A.M. to 02:30 P.M.

Eris Lifesciences Ltd's board approved and recorded the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. An interim dividend of ₹7.21 per share (721%) was declared for FY26-27, with a record date of May 29, 2026, and payment on or before June 19, 2026. The audit reports submitted have unmodified opinions. The board meeting occurred on May 20, 2026, from 11:00 A.M. to 02:30 P.M.

Eris Lifesciences Ltd's board approved and recorded the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. They declared an interim dividend of ₹7.21 per share (721%) on equity shares of Re. 1 each for FY 2026-2027. The record date for dividend eligibility is May 29, 2026, with payment on or before June 19, 2026. The board meeting was held on May 20, 2026, from 11:00 A.M. to 02:30 P.M. The audit reports have unmodified opinions.

Eris Lifesciences Ltd's board approved and recorded the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board also declared an interim dividend of ₹7.21 per share (721%) for FY26-27, with a record date of May 29, 2026, and payment on or before June 19, 2026. The audit reports are submitted with unmodified opinions.

Eris Lifesciences Ltd has scheduled a Board of Directors meeting on May 20, 2026, to consider and approve the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026. The board will also consider the declaration of an interim dividend for the financial year 2026-27. The trading window is closed from April 1, 2026, and will remain closed until 48 hours after the declaration of the financial results.

Eris Lifesciences announced that HALMED, the Croatian Agency for Medicinal Products and Medical Devices, inspected its subsidiary Swiss Parenterals Ltd.'s manufacturing facilities in Ahmedabad from March 9th to 13th, 2026. The company has received a list of non-compliance observations, which are described as procedural and requiring improvements to meet GMP standards. Eris Lifesciences plans to respond to HALMED within stipulated timelines, execute remediation actions, and submit CAPAs to request a follow-on inspection. The company anticipates minimal impact on its existing business but a potential delay in the commercialization of its EU-CDMO product pipeline. Eris Lifesciences is committed to maintaining high manufacturing standards and will provide further updates.

Eris Lifesciences Ltd has announced the completion of the acquisition of the Probiotics Business of Velbiom Probiotics Private Limited. This development is in line with the earlier intimation made by the company on March 20, 2026. The transaction has now been successfully closed, as per the company's latest update.